Cross-Country Healthcare Shareholders Greenlight Aya Healthcare Transaction: A New Era in Healthcare Services

Cross Country Healthcare Completes Stockholder Approval for Proposed Acquisition by Aya Healthcare Cross Country Healthcare, Inc., a leading provider of healthcare staffing services in the United States, recently announced that it has obtained all necessary stockholder approvals for its proposed acquisition by Aya Healthcare, a leading technology-enabled healthcare workforce solutions company. The transaction is expected…

Read More

Tharimmune Presents Positive TH104 Phase 1 Clinical Results at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune, Inc. Presents Positive Phase 1 Data for Lead Candidate TH104 at ACG 2024 Meeting Development of TH104 Tharimmune, Inc. recently announced the positive results from the Phase 1 trial of TH104, the Company’s lead candidate for moderate-to-severe pruritus in chronic liver disease. The trial demonstrated that TH104 showed no opioid withdrawal effects, reinforcing its…

Read More

Fluence Unveils India Innovation Centre: Empowering Global Growth and Expansion

Fluence Announces Opening of India Innovation Centre to Support Rapid Expansion of Global Operations Fluence’s India Innovation Centre, located in Bangalore, will serve as a global center of excellence to support Fluence’s rapid growth in providing customers with market-leading energy storage products, services, and software. This strategic move highlights Fluence’s commitment to innovation and excellence…

Read More

Argenx Showcases Pioneering Role in FcRn Therapy: Long-Term Data and Remarkable Patient Success Stories at AAN 2025

Argenx’s VYVGART®: New Data at AAN Annual Meeting, March 2025 Amsterdam, The Netherlands – Argenx SE, a leading global immunology company, is set to unveil new clinical trial and real-world data on its groundbreaking treatment, VYVGART® (efgartigimod alfa-fcab), and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), at the American Academy of Neurology (AAN) Annual Meeting in…

Read More

Important Notice for Outlook Therapeutics Inc. (OTLK) Investors: Class Action Lawsuit Filed by Kirby McInerney LLP – Act Now Before January 2nd!

Kirby McInerney LLP Reminds Investors of Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK) New York, Dec. 12, 2023 (GLOBE NEWSWIRE) – The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired…

Read More

“Kopin Corporation: A Promising Future Ahead as Trump’s “America First” Policy Boosts Global Defense Investment”

Welcome to the Future of Defense Technology Capitalizing on Global Demand In recent years, Kopin Corporation has emerged as a key player in the global defense market, particularly in advanced display technology for military applications. The company’s dedication to innovation and cutting-edge solutions has driven its defense sector revenue to unprecedented levels, with a staggering…

Read More